Esperion Therapeutics, Inc. (ESPR)
| Market Cap | 491.64M +158.9% |
| Revenue (ttm) | 403.14M +21.3% |
| Net Income | -22.68M |
| EPS | -0.11 |
| Shares Out | 257.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,280,505 |
| Open | 1.880 |
| Previous Close | 1.910 |
| Day's Range | 1.880 - 2.040 |
| 52-Week Range | 0.693 - 4.175 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 8.75 (+358.12%) |
| Earnings Date | May 7, 2026 |
About ESPR
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its product... [Read more]
Financial Performance
In 2025, Esperion Therapeutics's revenue was $403.14 million, an increase of 21.31% compared to the previous year's $332.31 million. Losses were -$22.68 million, -56.17% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ESPR stock is "Strong Buy." The 12-month stock price target is $8.75, which is an increase of 358.12% from the latest price.
News
Esperion to Report First Quarter 2026 Financial Results on May 7
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
Esperion Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference
Significant revenue growth and strategic expansion were highlighted, including the acquisition of Corstasis and the upcoming launch of Enbumyst for heart failure. Updated treatment guidelines and international launches are expected to drive further growth, while pipeline advancements and manufacturing improvements support long-term profitability.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty fi...
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
– Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued...
Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolem...
Esperion Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Strong revenue and prescription growth were highlighted, alongside the strategic acquisition of Corstasis and its novel nasal diuretic. Commercial and international expansion, robust financials, and a focused pipeline underpin a long-term growth vision through 2040.
Esperion Therapeutics Earnings Call Transcript: Q4 2025
Record 2025 results driven by strong U.S. and international growth, strategic Corstasis acquisition, and robust pipeline progress. 2026 outlook remains positive with anticipated guideline updates and continued expansion.
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –
Esperion Therapeutics Transcript: M&A announcement
The acquisition of Corstasis and ENBUMYST expands the cardiovascular portfolio with a unique nasal spray diuretic, leveraging existing infrastructure for rapid market entry. The deal features $75M upfront, milestone payments, and strong IP, targeting a $5B U.S. market and sustainable profitability by 2026.
Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)
ANN ARBOR, Mich. & HENDERSON, Nev.--(BUSINESS WIRE)-- #CHF--Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative o...
Esperion to Participate in The 2026 Citizens Life Sciences Conference
ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, ...
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040
ANN ARBOR, Mich., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resolve...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on February 10, 2026, the Company granted 11 new employees 40,200 restricted stock units (RSUs) under E...
Esperion Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Vision 2040 targets sustainable profitability by 2026 and at least five marketed products by 2040, driven by strong commercial execution, global expansion, and disciplined financial management. The bempedoic acid franchise is expanding rapidly, with new therapies and pipeline assets advancing toward late-stage development.
Esperion Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 –
Esperion Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Label expansion and strong clinical data have driven significant growth and broadened market reach, with influential guidelines and robust payer access supporting further adoption. International markets are performing well, and new pipeline products are on track for late 2020s launches.
Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company's partner in Canada for the development and commercializa...
Esperion Therapeutics Transcript: Jefferies London Healthcare Conference 2025
A major label update in 2024 expanded the market and drove strong growth, with U.S. guidelines expected to further boost adoption in 2026. The company is expanding its salesforce, targeting profitability, and advancing a pipeline in rare diseases while maintaining a strong cash position.
Esperion Therapeutics Transcript: KOL Event
Statin intolerance and refusal present a significant care gap, with bempedoic acid-based therapies offering effective, well-tolerated oral alternatives. Improved access, strong clinical data, and new guidelines support broader adoption, but education and combination strategies are key to maximizing impact.
Esperion Therapeutics Earnings Call Transcript: Q3 2025
Q3 2025 revenue surged 69% year-over-year to $87.3M, driven by strong U.S. and international growth, expanded payer coverage, and strategic investments. One-time costs impacted net income, but profitability is expected in Q1 2026 as margins improve and new guidelines boost demand.
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientifi...
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday.
Esperion Announces Pricing of Public Offering of Common Stock
ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing...
Esperion Announces Proposed Public Offering of Common Stock
ANN ARBOR, Mich., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (“Esperion”) (Nasdaq: ESPR), a commercial stage biopharmaceutical company that focuses on developing and commercializing...